This Bioengineering Research Partnership (BRP) will exploit emerging advances in semiconductor nanocrystal-based biomedical imaging to probe the tumor microenvironment and to develop therapeutic and diagnostic strategies. To accomplish this, we have assembled a multidisciplinary team of scientists and engineers at the Massachusetts General Hospital (MGH) and Massachusetts Institute of Technology (MIT) with a successful track record of basic and translational research. Over the past decade, this team has provided unprecedented insight into the nature of transport barriers in tumors (Nature Reviews Cancer, 2002). These exciting scientific findings resulted from innovations in intravital imaging (Nature Medicine, 1997, 2001, 2003, 2004), from exploiting molecular tools and quantum dot technology (Nature Medicine, 2005), and from the development of unique in vitro, in vivo, and mathematical models (PNAS, 1998, JCO, 2006). Our discoveries to date have led to novel strategies for improving drug delivery to tumors (Science, 2005). Development Cores led by M. Bawendi (an early pioneer of quantum dots) and D. Nocera at MIT are the corner stone of this BRP. They will develop novel nanocrystal (quantum dot) constructs, biosensors, and immunoconjugates which are not only essential for all three projects in this BRP but also provide a new direction in nanocrystal based bio-imaging by creating """"""""smart"""""""" nanocrystal probes of chemical and morphological environment. In Project 1, led by D. Fukumura and L. Munn, we aim to develop """"""""design rules"""""""" for nanoparticles and apply these rules to make """"""""smart"""""""" nanoparticles that, by changing their size and charge, can circumvent tumor barriers. In Project 2, led by R.K.Jain, we seek to map metabolic microenvironment of tumors with novel nanocrystal based biosensors and improve pH-sensitive chemotherapy and oxygen-sensitive radiation therapy. In Project 3, led by D. Duda and Y. Boucher, we harness the multiplexing capabilities of nanocrystal immunoconjugate probes and biosensors to develop in vivo multi-cell molecular and functional phenotyping techniques and establish a novel treatment strategy based on targeting stromal cells in tumors. A high level of scientific interaction among the three Projects, two Development Cores and four scientific Cores is a major strength of the BRP - as documented in joint publications by Project and Core leaders. Each Project will rely on multi-photon microscopy, mathematical modeling, and statistical support provided by Core A;cutting-edge molecular, cellular and histological expertise provided by Core B;superb surgical and animal support provided by Core C;and administrative support provided by Core D. We also have the resources and the clinical collaborators in place to readily take our scientific findings to clinical trials (Nature Medicine, 2004, Cancer Cell, 2007).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA126642-05
Application #
8235744
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Wolpert, Mary K
Project Start
2008-05-07
Project End
2014-02-28
Budget Start
2012-04-12
Budget End
2014-02-28
Support Year
5
Fiscal Year
2012
Total Cost
$1,507,967
Indirect Cost
$410,618
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Kloepper, Jonas; Riedemann, Lars; Amoozgar, Zohreh et al. (2016) Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A 113:4476-81
Incio, Joao; Liu, Hao; Suboj, Priya et al. (2016) Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. Cancer Discov 6:852-69
Askoxylakis, Vasileios; Ferraro, Gino B; Kodack, David P et al. (2016) Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. J Natl Cancer Inst 108:
Whitley, Melodi Javid; Cardona, Diana M; Lazarides, Alexander L et al. (2016) A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Sci Transl Med 8:320ra4
Fukumura, Dai; Incio, Joao; Shankaraiah, Ram C et al. (2016) Obesity and Cancer: An Angiogenic and Inflammatory Link. Microcirculation 23:191-206
Incio, Joao; Tam, Josh; Rahbari, Nuh N et al. (2016) PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity. Clin Cancer Res 22:2993-3004
Peterson, Teresa E; Kirkpatrick, Nathaniel D; Huang, Yuhui et al. (2016) Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci U S A 113:4470-5
Stylianopoulos, Triantafyllos; Economides, Eva-Athena; Baish, James W et al. (2015) Towards Optimal Design of Cancer Nanomedicines: Multi-stage Nanoparticles for the Treatment of Solid Tumors. Ann Biomed Eng 43:2291-300
Ager, Eleanor I; Kozin, Sergey V; Kirkpatrick, Nathaniel D et al. (2015) Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy. J Natl Cancer Inst 107:
Reiberger, Thomas; Chen, Yunching; Ramjiawan, Rakesh R et al. (2015) An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. Nat Protoc 10:1264-74

Showing the most recent 10 out of 118 publications